Principal Financial Group Inc. Buys 1,044 Shares of Sotera Health (NASDAQ:SHC)

Principal Financial Group Inc. boosted its stake in shares of Sotera Health (NASDAQ:SHC) by 0.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 391,779 shares of the company’s stock after acquiring an additional 1,044 shares during the quarter. Principal Financial Group Inc. owned about 0.14% of Sotera Health worth $7,017,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in SHC. Mendota Financial Group LLC bought a new position in shares of Sotera Health during the first quarter valued at approximately $67,000. BNP Paribas Arbitrage SNC bought a new position in shares of Sotera Health during the third quarter valued at approximately $37,000. MetLife Investment Management LLC bought a new position in shares of Sotera Health during the first quarter valued at approximately $139,000. Wells Fargo & Company MN grew its stake in shares of Sotera Health by 30.7% during the fourth quarter. Wells Fargo & Company MN now owns 6,455 shares of the company’s stock valued at $54,000 after buying an additional 1,518 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of Sotera Health during the first quarter valued at approximately $157,000. 88.89% of the stock is owned by institutional investors.

Sotera Health Trading Down 1.6 %

Sotera Health stock opened at $16.14 on Friday. The company has a quick ratio of 2.52, a current ratio of 2.73 and a debt-to-equity ratio of 5.46. Sotera Health has a 52 week low of $5.78 and a 52 week high of $19.40. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of -16.81 and a beta of 2.22. The stock has a 50-day moving average price of $17.79 and a 200 day moving average price of $16.81.

Sotera Health (NASDAQ:SHC) last released its earnings results on Thursday, August 3rd. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.02. Sotera Health had a positive return on equity of 48.61% and a negative net margin of 27.48%. The firm had revenue of $255.28 million during the quarter, compared to the consensus estimate of $261.05 million. Sell-side analysts anticipate that Sotera Health will post 0.75 EPS for the current year.

Analyst Upgrades and Downgrades

SHC has been the topic of several research analyst reports. Barclays dropped their price objective on Sotera Health from $21.00 to $20.00 in a research note on Thursday, May 4th. KeyCorp dropped their price objective on Sotera Health from $24.00 to $23.00 and set an “overweight” rating on the stock in a research note on Friday, August 4th. Finally, Royal Bank of Canada increased their price objective on Sotera Health from $18.00 to $22.00 and gave the stock an “outperform” rating in a research note on Friday, August 4th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.86.

About Sotera Health

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing. It also provides microbiological and analytical chemistry testing, and advisory services.